|
Following the settlement of the above, the Company's registered share capital is 9,029,557,071 ordinary shares of £0.01 each, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 9,025,476,866 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/9848E_1-2025-4-14.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
Enquiries
Investors Media
Jo Russell +44 7787 392441 Zoë Bird +44 7736 746167
Rakesh Patel +44 7552 484646 Victoria Durman +44 7894 505730
Emma White +44 7823 523562
Email: investor-relations@haleon.com Email: corporate.media@haleon.com
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
|
